Survodutide's new diabetes trial found weight loss and lower blood sugar. But stomach and bowel side effects led 18% of participants receiving it to stop treatment. The headline was up to 13.1% average weight loss. The broader analysis, which counts treatment stops, reported up to 9.8%.
Survodutide remains investigational, meaning it is still being tested, and is approved nowhere. For someone prescribed tirzepatide or semaglutide, these results describe a possible future option. They don't establish that switching would work better.
What happened: the new survodutide results
As of October 1, 2026, the day this article was written, Boehringer Ingelheim and Zealand Pharma have announced SYNCHRONIZE-2 results at the diabetes meeting in Milan. The NEJM paper, published October 1, 2026, appeared the same day.
This was a phase 3 trial, a large, late-stage human study. Adults with type 2 diabetes and overweight or obesity received weekly survodutide or placebo, an injection without the active drug, for 76 weeks. Assigned survodutide doses were 3.6 mg and 6.0 mg. These describe the experiment, not a personal dosing plan.
The company describes 755 participants. The study met both main goals: average weight change and the share losing at least 5% of starting weight.
Why the headline and the paper show different numbers
An estimand is the question a trial calculation answers. The paper's treatment-regimen estimand counts outcomes whether people continued treatment, stopped or interrupted it, or used other weight-management medicines.
Under that broader calculation, average weight loss at 76 weeks was 9.8% with the 6.0 mg dose, versus 3.9% with placebo.
The October 1 company announcement highlights the efficacy estimand. That calculation assumes people remained on treatment throughout. It reported up to 13.1% average loss versus 3.1%, and up to 79.3% reaching 5% loss versus 32.7%.
Those are different questions, not interchangeable estimates. The release also labels that analysis's statistical tests nominal: they weren't adjusted to account for testing multiple comparisons.
What the result means for today's medicines
Survodutide is a glucagon/GLP-1 dual agonist: one molecule switches on two hormone receptors, the places cells receive signals. GLP-1 helps regulate appetite and blood sugar. Glucagon helps the liver release stored fuel; its role in energy use is also being studied.
Tirzepatide activates GLP-1 and GIP, another gut hormone involved in blood sugar regulation. Semaglutide activates GLP-1 alone. Two drugs can each act on two receptors and still work differently.
For someone considering tirzepatide, the news adds another approach under study. It doesn't change what their existing prescription contains or how their provider sets treatment.
Survodutide vs tirzepatide and semaglutide: fair comparisons
The relevant comparison is with trials that also enrolled people with type 2 diabetes. Even then, comparisons across separate studies are weak.
In SURMOUNT-2, 938 adults received tirzepatide or placebo for 72 weeks. Average weight loss was 12.8% with 10 mg and 14.7% with 15 mg, versus 3.2% with placebo. Those were treatment-regimen figures (Garvey and colleagues, The Lancet, 2023). The SURMOUNT-2 results guide covers that trial in detail.
In STEP 2, 1,210 adults received semaglutide or placebo for 68 weeks. The 2.4 mg group averaged 9.6% weight loss versus 3.4% with placebo, also under a treatment-regimen analysis (Davies and colleagues, The Lancet, 2021).
Different starting blood sugar, background medicines, study lengths and treatment stops can change those averages. SYNCHRONIZE-2 tested neither tirzepatide nor semaglutide as its comparison drug. The numbers cannot declare a winner.
Why weight loss is often smaller with diabetes
Part of the explanation may be that better blood sugar control reduces sugar lost in urine. The body keeps calories it previously lost. Other medicines and differences in how the body handles insulin may contribute too.
A 2025 SURMOUNT-2 analysis in Diabetes Care found greater weight reduction among people with lower starting blood sugar. It was an analysis done after the trial, so it suggests explanations rather than proving them. A smaller average isn't evidence of less effort.
For someone considering semaglutide, STEP 2 offers context from people who actually had diabetes. Results from a trial excluding diabetes answer a different question.
Survodutide side effects: the 18% dropout matters
About 1 in 5 survodutide participants stopped treatment because of gastrointestinal events, meaning stomach or bowel problems. The company reported 18%, compared with 1.2% on placebo. That figure combines survodutide recipients; it isn't a separate rate for each dose.
Nausea, vomiting, diarrhea and constipation were common. The release describes these events as mostly mild to moderate, but some still made continued treatment difficult.
According to the release, stops usually happened while doses were increasing. The study’s rules offered limited flexibility for managing symptoms. Future studies allow more flexible increases, but that does not establish a lower dropout rate yet.
For a reader, this is the practical tradeoff: a weight-loss average doesn't describe whether a medicine is manageable day after day.
What the news does not mean
It doesn't establish that diabetes disappears. HbA1c is a blood test reflecting average blood sugar over roughly three months. The starting average was 7.4%.
The release's continued-treatment analysis reported up to a 1.21-point drop versus 0.03. Those are percentage-point changes. Blood sugar measured during treatment cannot establish what happens without medicine.
It also doesn't turn online survodutide into the product studied in this trial. The manufacturer's trial supply and a vial sold outside that program are different things.
Other developments have their own evidence: the retatrutide diabetes trial and VK2735 results explain those separate programs.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. Compounding means a pharmacy prepares a medication for an individual prescription. These survodutide results do not establish outcomes for those formulations.
As checked October 1, 2026, FDA explains that it does not review compounded drugs for safety, effectiveness or quality before marketing. A licensed provider may still prescribe an appropriate compounded tirzepatide or semaglutide formulation; that decision is between you and your doctor.
What to watch next
Boehringer expects SYNCHRONIZE-CVOT results later in 2026, according to the October 1 release. That is a cardiovascular outcomes trial, a study tracking heart and blood-vessel events. The expectation is a company timeline, not a result or a prescription availability date.
The next useful questions are whether benefits extend to those events and whether more flexible dose increases improve tolerability, meaning how manageable side effects are.
Today's conversation still concerns current medicines, blood sugar, weight goals and side effects. The prescriber sets the actual dose. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
